



## **Myriad Genetics to Present at the JPMorgan Healthcare Conference on January 8, 2007**

SALT LAKE CITY, January 2, 2007—Myriad Genetics, Inc. (NASDAQ: [MYGN](#)) announced today that its President and CEO, Peter Meldrum, is scheduled to present an overview of the Company at the 25th Annual JPMorgan Healthcare Conference, at 8:00 am Pacific Time on January 8, 2007, at the Westin St. Francis Hotel in San Francisco.

A live audio webcast of this presentation will be available online and can be accessed through a link on Myriad's home page at [www.myriad.com](http://www.myriad.com). The presentation will also be recorded for replay, and can be accessed under the Investor Relations heading of Myriad's web site, beginning several hours after the live presentation.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets [molecular diagnostic products](#), and is developing and intends to market therapeutic products, including Flurizan, our lead candidate for the treatment of [Alzheimer's disease](#). Myriad's news and other information are available on the Company's Web site at [www.myriad.com](http://www.myriad.com).

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These include, but are not limited to, uncertainties as to the extent of future government regulation of Myriad Genetics' business; uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds, which it develops, at acceptable prices; and the risk that the Company will not be able to sustain revenue growth for its predictive medicine business and products. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2006. All information in this press release is as of January 2, 2007, and Myriad undertakes no duty to update this information unless required by law.